Does tesamorelin work? In the population studied most carefully—adults with HIV-associated lipodystrophy—it reduced CT-measured visceral abdominal fat by roughly 11% to 15% after 26 weeks. The effect was maintained with continued treatment and faded after treatment stopped. That is a meaningful trial signal, but a narrow one: it does not show predictable weight loss, a permanent change, or the same outcome in people without HIV-associated lipodystrophy.
What counts as tesamorelin working?
Tesamorelin is a growth hormone-releasing hormone analog. It prompts the pituitary to release growth hormone, which raises insulin-like growth factor 1, or IGF-1. The full mechanism belongs in what tesamorelin does; the practical point here is that a hormone response and a clinical result are different endpoints.
A clinician can look at three layers: whether IGF-1 changes, whether a CT or MRI shows less visceral fat, and whether the result matches the reason treatment was considered. Scale weight and waist appearance are not substitutes for imaging because visceral fat lies around the organs, beneath the abdominal wall. The dedicated guide to tesamorelin for belly fat explains that distinction and the headline fat-loss numbers in depth.
Does tesamorelin work in phase 3 trials?
The strongest answer comes from two randomized, placebo-controlled phase 3 programs. Both enrolled adults with HIV and excess abdominal fat associated with antiretroviral treatment. They did not enroll a general weight-loss population.
| Trial | Participants and follow-up | Main finding | What it establishes |
|---|---|---|---|
| Falutz et al., New England Journal of Medicine, 2007 | 412 adults, 26 weeks | Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo | A CT-measured visceral-fat effect in adults with HIV and abdominal fat accumulation |
| Falutz et al., JAIDS, 2010 | 404 adults, 26 weeks plus a 26-week extension | Visceral fat fell 10.9% with tesamorelin and 0.6% with placebo at 26 weeks; the reduction reached about 18% among those continuing for 12 months | Replication in a second large trial and evidence that continued treatment maintained the change |
The 2007 NEJM trial also found an 81% rise in IGF-1 versus a 5% decline with placebo. The second trial and its extension reported that the initial visceral-fat improvement was rapidly lost among participants switched from tesamorelin to placebo.
A pooled analysis of both phase 3 trials included 806 participants. At week 26, the treatment effect on visceral fat was 15.4%; abdominal subcutaneous fat did not change significantly. Participants who continued treatment maintained a mean 17.5% visceral-fat reduction at week 52. These are group averages, not a forecast for one person.
Does adding ipamorelin strengthen the verdict?
There is no phase 3 trial showing that a tesamorelin-ipamorelin combination produces the same visceral-fat result, improves it, or follows the same timeline. Ipamorelin acts through a different growth-hormone signaling route, but a plausible pairing is not comparative evidence. The phase 3 numbers belong to tesamorelin alone in the studied HIV population. Tesamorelin and ipamorelin covers why a prescriber might discuss the combination and where its evidence stops.
How long does tesamorelin take to work?
Biochemical changes can appear before a body-composition endpoint. In a two-week study of 13 healthy men, mean overnight growth hormone measures increased and IGF-1 rose by 181 micrograms per liter. That small study shows early biological activity, not visible fat loss and not an individual treatment deadline.
The pivotal trials measured their main visceral-fat endpoint at 26 weeks. Their extensions followed participants to 52 weeks. A realistic evidence-based timeline is therefore weeks for a possible laboratory signal and months for an imaging-based body-composition assessment. The studies do not support judging the medication by a sensation, a photograph, or a promised number of days.
Stopping also belongs in the timeline. In both phase 3 extensions, visceral fat reaccumulated when participants who had received tesamorelin switched to placebo. The data support an on-treatment effect rather than a permanent reset.
What the liver study adds—and what remains unstudied
A 2019 randomized trial asked a different question in people who had both HIV and nonalcoholic fatty liver disease. Among 60 randomized participants, tesamorelin produced a 4.1-percentage-point greater absolute reduction in hepatic fat fraction than placebo at 12 months, equivalent to a 37% relative treatment effect. Hepatic fat fell below the study's 5% threshold in 35% of the tesamorelin group and 4% of the placebo group (Stanley et al., The Lancet HIV, 2019).
That trial broadens the outcomes measured, not the population. Its participants still had HIV. The phase 3 program did not establish tesamorelin for general obesity, ordinary age-related abdominal fat, or people seeking a lower number on the scale. Smaller studies outside HIV have explored selected populations, but there is no comparable phase 3 evidence for general weight loss.
Approval answers a narrower question than the search does
As of September 2026, Egrifta is FDA-approved; compounded tesamorelin is not. The FDA prescribing information limits Egrifta WR to reducing excess abdominal fat in adults with HIV and lipodystrophy and states that it is not indicated for weight-loss management because it has a weight-neutral effect.
A compounded preparation is a different product and does not inherit the brand's reviewed indication. A licensed provider may still prescribe a compounded formulation after an individual review; that decision is between the patient and the doctor. Monitoring commonly centers on the intended endpoint, IGF-1 and glucose rather than appearance alone. Tesamorelin side effects covers the safety questions that belong alongside the evidence verdict.
What a useful tesamorelin verdict looks like
The honest verdict is specific. Tesamorelin produced reproducible visceral-fat reductions over 26 weeks in large trials of adults with HIV-associated lipodystrophy. Continued treatment maintained the mean reduction to 52 weeks; withdrawal data showed reaccumulation. A smaller HIV/NAFLD trial also found less liver fat at 12 months. None of that guarantees weight loss or extends automatically to a person outside those populations.
At Promise, a licensed provider reviews every request and prescribes only when tesamorelin is medically appropriate; not everyone qualifies. If prescribed, the provider sets the regimen and defines how response will be measured rather than borrowing a trial schedule as personal dosing instructions.